The Claim
In patients with mild Alzheimer’s disease, intravenous laromestrocel treatment is associated with a statistically significant improvement in the Montreal Cognitive Assessment (MoCA) score at 39 weeks compared to placebo, with a mean difference of 2.1 points (P=0.015) in the combined treatment group.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with mild Alzheimer’s disease, intravenous laromestrocel treatment resulted in a 2.1-point higher Montreal Cognitive Assessment score at 39 weeks compared to placebo, with statistical significance.
See the scientific wording
In patients with mild Alzheimer’s disease, intravenous laromestrocel treatment is associated with a statistically significant improvement in the Montreal Cognitive Assessment (MoCA) score at 39 weeks compared to placebo, with a mean difference of 2.1 points (P=0.015) in the combined treatment group.
Infused cells release molecules that stop a key blood vessel receptor from breaking apart, which keeps blood vessels in the brain healthy and reduces inflammation. This protects brain tissue from shrinking and allows memory and thinking skills to improve.
What the research says
1 studyPeople with early Alzheimer’s who got this cell treatment scored better on memory and thinking tests after nine months than those who got a fake treatment, and the difference was real and not due to chance.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.